Break Through Cancer
Radical Collaboration
One Surgery Could Prevent Most Ovarian Cancers, Surgeons Say November 17, 2025 Expanding access to fallopian tube removal during planned abdominal surgeries in post-reproductive women could save thousands of lives every year. Read More at American College of Surgeons...
Real-Time Biopsies Reveal Hidden Insights into Glioblastoma Therapy Response October 08, 2025 In a groundbreaking advancement for glioblastoma research, scientists from Break Through Cancer’s Accelerating Glioblastoma Therapies Through Serial Biopsies TeamLab have demonstrated that the oncolytic virus therapy, CAN-3110, sparks a profound and previously undetectable immune response deep within recurrent glioblastoma tumors. Read More at Bioengineer.org...
Experimental Glioblastoma Trial Findings Could Lead to Change in Patient Monitoring and Therapy October 08, 2025 Researchers headed by teams at Mass General Brigham Cancer Institute and Harvard Medical School have acquired serial biopsies from two recurrent glioblastoma (rGBM) patients who were involved in an immunotherapy clinical trial, allowing the scientists to safely monitor brain tumor progression and the patients’ responses to treatment. The researchers say their approach captured details that are indiscernible by even the most advanced of imaging methods. Read More at Genetic Engineering and Biotechnology News...
Serial Biopsies Reveal Immune Activation During Treatment for Recurrent Glioblastoma October 08, 2025 by Mark Chiang A recent multi-institutional study has demonstrated that repeated sampling of brain tumor tissue can reveal immune system activation in response to cancer treatment for patients with recurrent glioblastoma (GBM). The research, conducted by the Accelerating GBM Therapies Through Serial Biopsies TeamLab and led by investigators from the Mass General Brigham Cancer Institute, highlights the potential of serial biopsies to detect treatment responses that may not be visible through traditional imaging techniques. Read More at Gene Online...
Real-Time Biopsies Uncover Hidden Response to Glioblastoma Therapy Early clinical trial results show that serial brain biopsies reveal immune activity in brain cancer not captured by standard scans News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org (CAMBRIDGE, MASS.) October 08, 2025 – A new study led by Break Through Cancer’s Accelerating Glioblastoma (GBM) Therapies Through Serial Biopsies TeamLab has revealed that an engineered virus therapy, CAN-3110, triggered powerful immune responses deep inside glioblastoma tumors that were invisible to standard imaging like MRI, according to early analyses of two patients with recurrent GBM. Published today in Science Translational Medicine,......
Break Through Cancer launches a $15M multi-institute pediatric osteosarcoma research initiative September 26, 2025 Vol.51 No.35 Break Through Cancer has launched the Defying Osteosarcoma TeamLab, an initiative that brings together more than 20 researchers from eight institutions in a coordinated, multi-year effort focused on improving pediatric osteosarcoma care. Read More at The Cancer Letter...
Can a virtual team of researchers break a 40-year logjam in this rare cancer? John Carroll August 25, 2025 When Mac Tichenor’s son Willie died of osteosarcoma at the age of 19 back in 2006, oncologists still relied on a decades-old chemo regimen called MAP — high-dose methotrexate, combined with doxorubicin and cisplatin. Typically, for young patients with the rare bone cancer, it staved off death for a while. Read More at Endpoints News...
Detecting minimal residual disease may be key to preventing ovarian cancer recurrence By Josh Friedman Fact checked by Heather Biele August 27, 2025 Key takeaways: Women who had minimal residual disease following first-line ovarian cancer treatment had significantly worse OS. Many women who appeared in remission had surgically- or ctDNA-detected minimal residual disease. Read More at Healio...
A New Approach to Undetectable Ovarian Cancer Author: Amir Jazaeri, MD Fact checked by: Sabrina Serani August 23, 2025 Amir Jazaeri, MD, of MD Anderson Cancer Center, provides an in-depth perspective on the complex challenges of treating ovarian cancer. He explains that a majority of patients are diagnosed with advanced-stage disease, meaning the cancer has already spread extensively throughout the abdomen and possibly to other parts of the body. Despite this initial widespread nature, a combination of radical surgery and six cycles of platinum-based chemotherapy is often highly effective, leading to a state of remission where patients are considered cancer-free. Read......
The Prognostic Value of Residual Disease in Ovarian Cancer Authors: Sabrina Serani & Amir Jazaeri, MD Fact checked by: Jason M. Broderick August 22, 2025 Key Takeaways SLL and ctDNA are effective in detecting MRD in ovarian cancer, surpassing conventional methods like CA 125 and CT scans. SLL provides access to MRD tissue, offering insights into chemoresistance and potential therapeutic targets. CtDNA is a promising early surrogate endpoint in clinical trials, allowing earlier assessment of treatment efficacy. Identifying high-risk patients through these methods enables earlier intervention with innovative and investigational therapies. Read More at Targeted Oncology...
Break Through Cancer
101 Rogers Street
Suite 3A
Cambridge, MA 02142
Info@breakthroughcancer.org
1-800-757-9881
Quick Links
Annual Reports
